Internal Medicine, Medical Oncology · Fort Myers, FL
NPI
1407085376
Since 2009
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
8260 Gladiolus Dr
Fort Myers, FL, 33908
Phone (239) 437-5755
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.7M
395,178 services
Medicare patients, 2024
1,382
Average age 77
Drug cost, 2024
$9.4M
1,945 prescriptions
Company payments, 2025
$5,738
From 51 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raymond M Esper was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 97,410 times for 85 patients. In total Raymond M Esper billed 395,178 services in 172 codes, and Medicare paid $6.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-17.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 97,410 | 85 | $0.28 | $27K |
| J0896 Injection, luspatercept-aamt, 0.25 mg | Office | 42,200 | 21 | $31.62 | $1.3M |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,200 | 25 | $44.66 | $813K |
| J9299 Injection, nivolumab, 1 mg | Office | 17,740 | 11 | $24.54 | $435K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 15,130 | 77 | $6.42 | $97K |
| J9025 Injection, azacitidine, 1 mg | Office | 14,700 | 14 | $0.30 | $4,355 |
| J1756 Injection, iron sucrose, 1 mg | Office | 8,800 | 28 | $0.16 | $1,419 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 7,740 | 17 | $34.04 | $264K |
| J0897 Injection, denosumab, 1 mg | Office | 7,500 | 58 | $20.45 | $153K |
| J0185 Injection, aprepitant, 1 mg | Office | 6,110 | 21 | $1.34 | $8,171 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 4,630 | 16 | $5.80 | $27K |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,586 | 13 | $0.08 | $366 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,188 | 79 | $0.09 | $286 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2,854 | 12 | $35.60 | $102K |
| 85025 Blood Count | Office | 2,762 | 957 | $7.56 | $21K |
By year: 2022 $6.5M for 497,056 services; 2023 $5.7M for 438,904 services; 2024 $6.7M for 395,178 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,762 | 957 | $7.56 | $21K |
| 36415 Venipuncture Blood Collection | 2,538 | 947 | $8.64 | $22K |
| 85046 Blood Count | 1,288 | 375 | $5.43 | $6,995 |
| 81003 Clinical Chemistry | 47 | 19 | $2.20 | $103 |
Medicare prescription drug claims, 2024
In 2024, the drug Raymond M Esper prescribed most often to Medicare patients was Acyclovir, with 131 prescriptions and refills. In total Raymond M Esper wrote 1,945 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 131 | 208 | 25 | $1,312 |
| Duloxetine Hcl Generic | 130 | 220 | 42 | $1,855 |
| Letrozole Generic | 129 | 342 | 43 | $3,814 |
| Dexamethasone Generic | 127 | 150 | 33 | $1,398 |
| Hydroxyurea Generic | 116 | 238 | 28 | $3,202 |
| Revlimid Lenalidomide | 101 | 101 | 12 | $1.9M |
| Levothyroxine Sodium Generic | 63 | 139 | 21 | $396 |
| Imbruvica Ibrutinib | 57 | 57 | Under 11 | $841K |
| Ondansetron Hcl Generic | 52 | 52 | 25 | $320 |
| Prednisone Generic | 50 | 64 | 25 | $169 |
| Jakafi Ruxolitinib Phosphate | 49 | 49 | Under 11 | $863K |
| Eliquis Apixaban | 43 | 69 | 12 | $39K |
| Ondansetron Odt Ondansetron | 40 | 40 | 19 | $354 |
| Pomalyst Pomalidomide | 38 | 38 | Under 11 | $835K |
| Anastrozole Generic | 36 | 88 | Under 11 | $1,684 |
Brand drugs: - claims; generic drugs: 1,291 claims; opioid claims: 64.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raymond M Esper $5,738 ($5,738 in general payments such as food, travel and fees) from 51 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $480.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 19 | $480 |
| Janssen Biotech, Inc. JNJ | 28 | $449 |
| Merck Sharp & Dohme LLC MRK | 16 | $371 |
| Pfizer Inc. PFE | 19 | $370 |
| Astellas Pharma US Inc 4503.T | 17 | $358 |
| Celgene Corporation BMY | 11 | $296 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $279 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 16 | $207 |
| BeOne Medicines USA, Inc. ONC | 10 | $206 |
| Incyte Corporation INCY | 10 | $204 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.